Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
about
Axitinib for the management of metastatic renal cell carcinomaTargeting angiogenesis in squamous non-small cell lung cancerIncreased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motilityUnderstanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsAssociation of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies.Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale.Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of expertsRandomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).NAADP-Dependent Ca(2+) Signaling Controls Melanoma Progression, Metastatic Dissemination and NeoangiogenesisThe soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.Optimizing treatment for metastatic renal cell carcinoma.Tumor control versus adverse events with targeted anticancer therapies.Targeted therapies for renal cell carcinoma: review of adverse event management strategies.Pharmacokinetic evaluation of axitinib.Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.Protein kinase inhibitors in renal cell carcinoma.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Renal effects of targeted anticancer therapies.Axitinib in metastatic renal cell carcinoma.Emerging therapeutic approaches in renal cell carcinoma.Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report.Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?The use of sunitinib in renal cell carcinoma: where are we now?Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.Nintedanib in ovarian cancer.[Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic rAxitinib: in advanced, treatment-experienced renal cell carcinoma.
P2860
Q24613720-929560FF-AEFD-4D0B-9038-48A1911E5003Q26861341-ED45C177-93F5-4097-A751-D6B1DCAE6519Q28820722-8A388EE8-D213-4252-9876-012A37B9B8CFQ33698419-9A88E1ED-0096-4311-B08D-4774C7868405Q34013801-211FE024-9A26-47F8-A690-A8BE58A5E5DEQ34627828-406D8E54-E9C4-4B72-8567-3A47458D8780Q35311474-15EF7E1F-58D1-4D70-8711-A56E299B8FB4Q35602130-5ED1BC0F-3E11-437A-8AD6-4CC4FE8F7E11Q35654010-089B2F26-1ED6-4639-B445-E2601C3CF8C5Q35909225-BBBF5B03-DE6F-490B-969D-ACE26D1B2CDAQ36347314-C50A32FB-920E-4703-BFF0-8554DA3A6640Q36432462-2B3E17BC-0940-4682-A78D-38B09CCF7660Q37366977-ED048F96-6F65-4B93-9CB7-D941AA8FCBA7Q37562355-4F016F52-B50A-42C2-AEE7-B67FE6CC20A7Q37577963-4CBBD8A5-D92E-42E3-8B0F-A2A97292E2EAQ37799821-C79C7981-49FB-4500-96EB-681921AFE3E2Q37875792-6A71352B-EC23-439B-9446-4DCF2182F167Q37898560-F3837618-981E-4728-A524-0966B020EBF7Q37960915-0F795F43-90FD-4D34-9A56-92939720DBD0Q37969899-1BDBE362-2210-45BB-AA71-4B4D89C9ED8DQ37974894-7554C139-22F6-486F-A460-AD86D52A0E53Q37976135-4BC1B04D-7DE9-4D02-B852-248931A1ACBBQ38004605-F396E37F-7332-4EAF-9F04-620250CA9EE9Q38012779-5638BC24-7132-4F1F-BFB0-E24F07FF1D48Q38170411-FF395706-C90B-4904-AA3F-9B34234A7146Q38196855-7BE6E6DC-4357-4DB3-92BC-3C56AD0E4A9EQ38367168-108B25B3-C792-4637-B6F0-CFF0549B099AQ38439661-8146D2A4-87F6-430E-8AD5-F3B37937975FQ38587958-19F7768B-ABAF-407E-9656-0BD59F4AA9B2Q38645097-EBD1D5F5-8432-4216-ACB3-A40B0650EACDQ39172001-4DA2A688-8807-4531-9709-FBF7794A6CD2Q39911811-D6581B1F-3BEE-4DE9-AC80-93B22C62C36EQ41920336-C2300AAD-C068-4EF7-8B2C-2E18120DF672Q48634468-B78764AF-B75C-40F9-A7D2-EA9AC566AD38Q49953442-6DA50FEC-7E5D-46C1-8087-82E065D93924Q51824301-8F64A4FE-4DAF-4B2D-8F36-04501B041B26Q53352740-CEDB590E-A756-4FE9-8CA2-31C37DCDDCDFQ54469002-889C870E-FD96-47B2-A4AB-9580D5B16858
P2860
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plethora of agents, plethora o ...... tastatic renal cell carcinoma.
@en
Plethora of agents, plethora o ...... tastatic renal cell carcinoma.
@nl
type
label
Plethora of agents, plethora o ...... tastatic renal cell carcinoma.
@en
Plethora of agents, plethora o ...... tastatic renal cell carcinoma.
@nl
prefLabel
Plethora of agents, plethora o ...... tastatic renal cell carcinoma.
@en
Plethora of agents, plethora o ...... tastatic renal cell carcinoma.
@nl
P1476
Plethora of agents, plethora o ...... tastatic renal cell carcinoma.
@en
P2093
Joaquim Bellmunt
Manuela Schmidinger
P304
P356
10.1016/J.CTRV.2010.01.003
P577
2010-02-16T00:00:00Z